BeOne Medicines Ltd. has achieved significant milestones in oncology, including European Commission approval for its cancer treatment TEVIMBRA and a strategic royalty agreement with Royalty Pharma worth up to $950 million.

BeOne Medicines Ltd. has secured a $950 million royalty deal with Royalty Pharma for its cancer treatment IMDELLTRA, providing a significant financial boost and enhancing the company’s growth potential.

BeOne Medicines Ltd. has expanded its partnership with Biocytogen in a licensing agreement to accelerate the development of innovative antibody-based cancer treatments.

BeOne Medicines Ltd has received FDA approval for its flagship cancer drug BRUKINSA, a major milestone that is expected to revolutionize cancer treatment and drive growth for the company.

BeOne Medicines Ltd has received FDA approval for its flagship cancer drug BRUKINSA, a major milestone that is expected to revolutionize cancer treatment and drive growth for the company.